北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2025 年第四次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话:010-52682888 传真:010-52682999 邮编:100033 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2025 年第四次临时股东会的法律意见 北京德恒律师事务所 关于中红普林医疗用品股份有限公司 2025 年第四次临时股东会的 法律意见 德恒 01G20250295-04 号 致：中红普林医疗用品股份有限公司 中红普林医疗用品股份有限公司（以下简称"公司"）2025 年第四次临时 股东会（以下简称"本次会议"）于 2025 年 12 月 25 日（星期四）召开。北京 德恒律师事务所（以下简称"德恒"）受公司委托，指派廖齐越律师、王瑞芸律 师（以下简称"德恒律师"），根据《中华人民共和国证券法》（以下简称"《证 券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、中国证 券监督管理委员会《上市公司股东会规则》（以下简称"《股东会规则》"）、 《中红普林医疗用品股份有限公司章程》（以下简称"《公司章程》"）的规定， ...

Core Insights - The global medical protective industry is undergoing significant transformation, with "Made in China" evolving into "Intelligent Manufacturing in China," allowing for greater influence in the global market [1] - Zhonghong Medical is strategically positioned to seize development opportunities through resource integration and technological innovation, addressing key pain points in the medical protection field [1] Group 1: Resource Integration and Innovation - Zhonghong Medical has strategically acquired Guilin Hengbao Health Protection Co., Ltd., a leader in the latex industry, to achieve a resource integration effect of "1+1>2" [2] - The acquisition enhances Zhonghong Medical's capabilities in large-scale production, global supply chain management, and market channel expansion, while Guilin Hengbao contributes its core technological advantages in surgical glove innovation [2] - This partnership creates a "technology + capacity + channel" development model, laying a solid foundation for future innovative product incubation and industrialization [2] Group 2: Addressing Industry Pain Points - Zhonghong Medical focuses on the critical issue of surgical glove rupture risk, leading to the successful development of a dual-layer, dual-color surgical glove under the Medispo brand [3] - The innovative glove design includes a green ultra-thin inner layer for operational flexibility and a white textured outer layer for improved instrument grip stability, along with a precision negative pressure system for immediate rupture alerts [3] - The product meets high-risk surgical protection standards and redefines safety benchmarks for surgical gloves, enhancing safety in operating rooms [3] Group 3: Global Expansion of "Intelligent Manufacturing in China" - Zhonghong Medical accelerates its global layout by promoting the Medispo brand, ensuring product quality aligns with international standards through cleanroom facilities and stringent quality control systems [4] - The dual-layer, dual-color surgical glove has gained international recognition, showcasing the strength of "Intelligent Manufacturing in China" [4] - The company's strategic resource integration, technological innovation, and global outreach represent a unique development path for the medical protection industry, positioning Zhonghong Medical to lead in global healthcare safety [4]

Core Viewpoint - Zhonghong Medical is focusing on the development of nuclear radiation protective gloves and has showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, indicating a diversification into the pet economy and medical device sectors [2][9]. Group 1: Business Overview - Zhonghong Medical primarily engages in the research, production, and sales of high-quality disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [9]. - The company operates mainly through ODM direct sales, producing for overseas medical device and consumable brand owners [3]. - As of September 30, 2025, Zhonghong Medical reported a revenue of 1.864 billion yuan, reflecting a year-on-year growth of 1.38%, while the net profit attributable to the parent company was -7.21 million yuan, a decrease of 114.13% year-on-year [10]. Group 2: Market Position and Financials - The company has a significant international presence, with overseas revenue accounting for 81.56%, benefiting from the depreciation of the RMB [4]. - Zhonghong Medical is a state-owned enterprise, ultimately controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5]. - The company has distributed a total of 1.251 billion yuan in dividends since its A-share listing, with 501 million yuan distributed over the past three years [11]. Group 3: Recent Developments - Zhonghong Medical is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, indicating a commitment to innovation in safety products [2]. - The company showcased its veterinary infusion pumps at a major pet expo, highlighting its entry into the pet healthcare market with products designed for safety and functionality [2].

证券代码：300981 证券简称：中红医疗 公告编号：2025-109 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 3. 注册资本：3,000 万人民币 4. 成立日期：2022 年 3 月 4 日 5. 公司类型：有限责任公司（非自然人投资或控股的法人独资） 6. 注册地址：海南省海口市秀英区秀英街道高新社区居委会科技大道 7 号 A 栋 5 楼 12 号 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议、2024 年第三次临时 股东大会，审议通过了《关于公司及子公司 2025 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为资产负债率 70%（含） 以上的控股子公司提供担保额度为不超过 15 亿元，为资产负债率低于 70%的控 股子公司提供担保额度为不超过 10 亿元，担保 ...

证券代码：300981 证券简称：中红医疗 公告编号：2025-108 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议、2024 年第三次临时 股东大会，审议通过了《关于公司及子公司 2025 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为资产负债率 70%（含） 以上的控股子公司提供担保额度为不超过 15 亿元，为资产负债率低于 70%的控 股子公司提供担保额度为不超过 10 亿元，担保额度总计不超过 25 亿元。具体内 容详见《关于公司及子公司 2025 年度向银行申请综合授信额度暨公司为子公司 申请综合授信额度提供担保的公告》（公告编号：2024-083）。 二、担保进展情况 近日，为满足公司全资子公司北京林普医疗用品有限公 ...

Core Viewpoint - The company, Zhonghong Medical, is actively involved in the development and production of medical devices and protective equipment, with a focus on international markets and innovative products [2][3][9]. Group 1: Company Overview - Zhonghong Medical is located in Tangshan, Hebei Province, and was established on December 22, 2010, with its stock listed on April 27, 2021 [9]. - The company's main business includes the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves, with health protection products accounting for 89.48% of revenue [9]. - As of September 30, 2025, the company reported a revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, but a net profit loss of 7.21 million yuan, a decrease of 114.13% year-on-year [10]. Group 2: Market Position and Financials - The company has a significant international presence, with overseas revenue accounting for 81.56% of total revenue, benefiting from the depreciation of the RMB [4]. - The company operates under an ODM direct sales model, producing medical devices and consumables for overseas brand owners [3]. - The company has distributed dividends totaling 1.251 billion yuan since its A-share listing, with 501 million yuan distributed over the past three years [11]. Group 3: Product Development and Innovations - Zhonghong Medical is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, addressing the technical needs for nuclear pollution prevention [2]. - The company showcased its veterinary infusion pumps at the 12th Beijing Pet Expo, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2].

Core Viewpoint - The company, Zhonghong Medical, is experiencing fluctuations in stock performance and is focusing on various innovative product developments in the medical and pet care sectors, while benefiting from the depreciation of the RMB and its status as a state-owned enterprise. Group 1: Company Performance - On December 15, Zhonghong Medical's stock fell by 1.03%, with a trading volume of 63.07 million yuan and a market capitalization of 5.755 billion yuan [1] - As of September 30, the company reported a revenue of 1.864 billion yuan for the first nine months of 2025, representing a year-on-year growth of 1.38%, while the net profit attributable to shareholders was a loss of 7.21 million yuan, a decrease of 114.13% year-on-year [10] - The company has a total of 22,400 shareholders, an increase of 11.24% compared to the previous period, with an average of 17,531 circulating shares per person, a decrease of 10.11% [10] Group 2: Business Operations - Zhonghong Medical primarily engages in ODM production for overseas medical devices and consumables, responsible for product design and manufacturing, while brand owners handle packaging and sales in international markets [3] - The company's main business revenue composition includes health protection products (89.48%), safety infusion products (6.22%), and innovative incubation products (4.30%) [9] - As of the 2024 annual report, overseas revenue accounted for 81.56% of total revenue, benefiting from the depreciation of the RMB [4] Group 3: Product Development and Innovation - The company is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, which includes a chemical protective layer, a white warning layer, and a nuclear radiation protective layer [2] - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2] Group 4: Shareholder and Market Dynamics - The company is state-owned, with the ultimate control held by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [5] - As of September 30, the top ten circulating shareholders include Hong Kong Central Clearing Limited and a newly entered medical device ETF [11]

Core Viewpoint - The company, Zhonghong Medical, is experiencing fluctuations in stock performance and is involved in various sectors including nuclear pollution prevention, pet economy, state-owned enterprise reform, and medical devices [2][3]. Group 1: Company Overview - Zhonghong Medical is a state-owned enterprise controlled by the Xiamen Municipal Government State-owned Assets Supervision and Administration Commission [3]. - The company specializes in the research, production, and sales of high-quality nitrile gloves, PVC gloves, and other disposable protective gloves, with a revenue composition of 89.48% from health protection products, 6.22% from safety infusion products, and 4.30% from innovative incubation products [8]. - As of September 30, the company reported a revenue of 1.864 billion yuan, a year-on-year increase of 1.38%, but a net profit loss of 7.21 million yuan, a decrease of 114.13% year-on-year [9]. Group 2: Market Performance - On December 12, Zhonghong Medical's stock fell by 3.21%, with a trading volume of 124 million yuan and a turnover rate of 2.29%, bringing the total market value to 5.815 billion yuan [1]. - The company has seen a significant portion of its revenue, 81.56%, coming from overseas sales, benefiting from the depreciation of the yuan [4]. - The average trading cost of the stock is 14.69 yuan, with recent trading showing a decrease in holdings but at a slowing rate; the stock price is approaching a resistance level of 13.68 yuan [7]. Group 3: Product Development and Innovation - The company is collaborating with Guilin University of Technology to develop a multi-layer nuclear radiation protective glove, which includes a chemical protective layer, a white warning layer, and a nuclear radiation protective layer [2]. - At the 12th Beijing Pet Expo, Zhonghong Medical showcased its veterinary infusion pumps, which feature IP34 waterproof design and dual CPU architecture, providing various infusion modes and safety features [2].

Group 1 - The core index of the Shenzhen-Hong Kong Stock Connect Medical Index closed at 4254.95 points, down 1.68%, with a trading volume of 8.905 billion HKD and a turnover rate of 1.12% [1] - Among the constituent stocks, 5 stocks increased, with Yimaitong leading the gain at 4.26%, while 52 stocks decreased, with Zhonghong Medical leading the decline at 6.1% [1] Group 2 - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 312 million HKD, while retail investors saw a net inflow of 339 million HKD [2] - The details of fund flows indicate that speculative funds had a net outflow of 26.8777 million HKD [2]

Core Viewpoint - Zhonghong Medical's stock price has declined, closing at 14.92 yuan with a drop of 3.24%, indicating a current state of underperformance since its IPO [1] Group 1: IPO and Initial Performance - Zhonghong Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1] - The stock reached a peak price of 159.80 yuan on its first trading day, marking the highest price since its listing [1] - Currently, the stock is in a state of decline, having fallen below its initial offering price [1] Group 2: Fundraising and Financials - The total amount raised from the IPO was 2.025 billion yuan, with a net amount of 1.896 billion yuan after expenses, exceeding the originally planned fundraising by 1.317 billion yuan [1] - The initial fundraising plan aimed to raise 580 million yuan for projects related to nitrile gloves and working capital [1] - The total issuance costs for the IPO were 128 million yuan, with underwriting fees accounting for 107 million yuan [1] Group 3: Dividend Distribution - In 2022, Zhonghong Medical announced a profit distribution plan, distributing 7.00 yuan in cash per 10 shares and increasing the total share capital by 9 million shares through capital reserve [2] - For 2021, the company distributed 30.00 yuan in cash per 10 shares and increased the total share capital by 13.33 million shares [2] - The 2024 profit distribution plan includes a cash dividend of 2.5 yuan per 10 shares and a capital reserve increase of 3.88 million shares, resulting in a total share capital of approximately 428.86 million shares [3]